Washington, DC (LifeNews.com) - A unanimous decision Thursday by a Food and Drug Administration advisory committe to recommend for approval a new abortion drug called ells is not setting well with pro-life groups. They are also upset that mainstream media outlets are falsely presenting the drug as an improved morning after pill.
The advisory Committee for Reproductive Health Drugs cast two 11-0 votes saying women could use the drug to prevent pregnancy when taken up to five days after intercourse.
The panel said the "investigational emergency contraceptive pill" known as ulipristal, that would potentially be sold under the name Ella in the United States, is safe and effective at preventing pregnancy.
Wendy Wright, the president of Concerned Women for America who testified before the committee yesterday, expanded on her initial comments to LifeNews.com.
She said members of the panel ignored the fact that the dug [sic] clearly works as an abortion pill by terminating the life of a newly-conceived human being.
Wright said the FDA panel wouldn't even go as far as considering publishing a warning label on the drug to inform women about potential problems or its abortifacient properties.
"Members voted for no negative info on the drug label because it would bias people against the drug. They even argued against doing studies on whether surviving babies have brith defects because, as one member said, negative outcomes are more likely to be reported than positive," she said.
At the same time, Erin Gainer, CEO of HRA Pharma, the maker of the Ulipristal abortion drug, applauded the decision.
"HRA Pharma is pleased with the outcome of the Advisory Committee's votes on the safety and effectiveness of ulipristal acetate," she said. "We look forward to working the the FDA to obtain approval for this new drug and offering a next-generation emergency contraceptive to women in the U.S."
But Wright said ella subjects women to problems after sexual assault as men obtain it in an attempt to cover their tracks by stopping the pregnancy.
Anna Glasier, of NHS Lothian in Edinburgh, led a study of more than 5,500 women in the UK published online in The Lanet medical journal. It found fewer pregnancies among those women given the ellaOne drug within five days of intervourse.
And for women who took the drug between 3-5 days after having sex, only women taking the traditional morning after pill became pregnant. They's [sic] because all of the women using ulipristal during that time period had abortions.